The European Society for Medical Oncology Congress 2025 (ESMO 2025) has announced its abstract selections, including four clinical studies of Chidamide (Epidaza®), a first-in-class therapy developed by Chipscreen Biosciences. These studies span four key oncology areas: relapsed/refractory NK/T-cell lymphoma, peripheral T-cell lymphoma, advanced sarcoma, and breast cancer. All studies explore the innovative “HDAC inhibitor + immunotherapy/chemotherapy” treatment strategy. Notably, the combination therapy study for relapsed/refractory NK/T-cell lymphoma has been selected for a featured oral presentation, with the relevant findings scheduled to be presented at the congress.

Four Studies Accepted, Continuing Breakthroughs in “HDAC+” Research

1 Proffered Paper session

Abstract No.: 1241O

Title: PD-1 Inhibitor (Tislelizumab) in Combination with Chidamide, Lenalidomide, and Etoposide for Relapsed/Refractory Extranodal NK/T-Cell Lymphoma (r/r-ENKTL): Preliminary Findings from a Prospective, Multicenter, Single-Arm Phase II Study

Presenting Author: Zhang Lei, The First Affiliated Hospital of Zhengzhou University

2. Mini Oral session

Abstract No.: 1245MO

Title: Chidamide Plus Mitoxantrone Hydrochloride Liposome in Relapsed or Refractory Peripheral T-Cell Lymphoma: Updated Phase II Study Results

Presenting Author: Li Zhiming, Sun Yat-sen University Cancer Center

Abstract No.: 2689MO

Title: A Phase II Clinical Trial of Chidamide Combined with Toripalimab for Advanced Soft Tissue Sarcoma

Presenting Author: Zhang Xing, Sun Yat-sen University Cancer Center

3. Poster

Abstract No.: 564P

Title: A Phase II Clinical Study of PD-1 Antibody Combined with Chidamide for Metastatic Triple-Negative Breast Cancer

Presenting Author: Yuan Zhongyu, Sun Yat-sen University Cancer Center

China's Original Innovation Accelerates Global Patient Access

The ESMO Congress 2025 will be held from October 17 to 21 in Berlin, Germany. As one of the world’s most prestigious oncology conferences, it brings together clinicians, researchers, and patients to showcase the latest breakthroughs and cutting-edge data. This year, Chinese researchers have secured 35 oral presentations. Chidamide has gained notable recognition across both hematologic and solid tumors, underscoring the cross-tumor potential of the “HDAC + IO/chemotherapy” strategy. The study on relapsed/refractory extranodal NK/T-cell lymphoma has been selected as one of the only two breakthrough achievements from China for ESMO’s hematology-focused invited oral presentations, alongside leading research from Europe and the United States. As the world’s first subtype-selective HDAC inhibitor, Chidamide uses a unique epigenetic modulation mechanism to reactivate the tumor immune microenvironment. Whether administered alone or in combination with other therapies, it has shown broad potential in malignant tumors, particularly in “HDAC + IO” approaches, offering patients new treatment options. Phase III clinical trials are currently underway for colorectal cancer, and an international collaborative Phase III study in melanoma is progressing systematically, paving the way for more diversified therapeutic solutions for patients.